ALTASCIENCES
13.5.2021 18:33:07 CEST | Business Wire | Press release
Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system.
Amy Denvir, General Manager of Altasciences’ Kansas City clinical site, says, “We are proud to partner with SiteOne Therapeutics and help move this important therapeutic into clinical trials. Helping bring to market a new approach that may provide a non-opioid option to treat moderate- to-severe pain is an exciting prospect, and we look forward to delivering this ground-breaking research. ”
Click here to read the SiteOne press release .
Altasciences has designed and conducted hundreds of first-in-human trials by offering comprehensive, full service, early development solutions. With a focus on developing sound strategies combined with operational efficiencies, the company minimizes the time taken to make critical go/no-go decisions by harmonizing clinical pharmacology services, biomarker capabilities, PK/PD analysis expertise, and program knowledge.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005827/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Surges in Oulu as European Capital of Culture Year Drives Record Visitor Numbers and Major Exhibitions5.5.2026 14:23:00 CEST | Press release
The European Capital of Culture year has boosted tourism and cultural attendance in Oulu, with strong growth in overnight stays, record-breaking visitor numbers and major exhibitions attracting local and international audiences. The year has started strongly in Oulu, Finland, with tourism and cultural attendance rising across sectors. In January–February, total overnight stays increased by more than 20%, while February alone saw a 32% increase, reaching 78,400 stays. International tourism grew by over 40%. At the same time, the opening festival in January attracted around 250,000 visits, highlighting strong interest among both residents and visitors and signalling a promising year for the city’s tourism sector. “The start of the year has clearly shown the power of culture in strengthening tourism and regional vitality,” says Oulu2026 Programme Director Samu Forsblom. “With hundreds of cultural operators across all 39 municipalities involved, this is a unique year to visit our region in
Fleet Launch Customer NetJets Takes Delivery of First Three Cessna Citation Ascend Midsize Business Jets5.5.2026 14:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone as the first three Cessna Citation Ascend business jets were delivered to fleet launch customer NetJets. NetJets, which operates the world's largest, most diverse private jet fleet, is the first private fleet operator to take delivery and begin operations with the Cessna Citation Ascend. Setting new standards in performance, comfort and operational efficiency for the midsize business jet market, the Citation Ascend builds on the longstanding relationship between Textron Aviation and NetJets by offering owners a seamless progression of advanced aircraft designed to deliver exceptional reliability, efficiency and luxury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505495566/en/ Fleet launch customer NetJets takes delivery of first three Cessna Citation Ascend midsize business jets. (Photo Credit: Textron Aviation) “The Citation Ascend re
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 14:00:00 CEST | Press release
Bracco's new BubbleGen technology streamlines cell therapy manufacturing for one-step cell separation and activation with no magnetic residualsBubbleGen microbubbles can target specific cell subtypes, including rare populationsDemos available for BubbleGen at ISCT, Booth #2711 Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative t
ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 13:12:00 CEST | Press release
ATLAS participated as an exclusive Cornerstone investor in United Utilities’ equity placement, expanding its existing investment to establish a significant minority shareholding.ATLAS was pleased with the strong support for the transaction from other long-term shareholders signalling broad support for United Utilities’ investment and growth strategy.United Utilities’ fully funded capital investment program underpins a strong multi-year growth trajectory1. ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critica
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 12:37:00 CEST | Press release
Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio developmentWith leadership experienceat Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ: BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR)and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her knowledge of the investment ecosystem to strengthen relationships with investors for both Jeito funds and its portfolio companiesSarah brings deep strategic expertise from senior roles at leading Biopharma investment firms - including as Partner, Marketing and Talent at Abingworth and as Chief Talent Officer at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom